Recombinant vaccinia viral vector vaccine expressing HPV16/18 E6/E7 tumor antigens used as a boost to enhance HPV-specific immune responses.
Recombinant vaccinia viral vector that delivers and expresses HPV16/18 E6/E7 tumor antigens in host antigen-presenting cells, leading to MHC I/II presentation and induction of HPV-specific CD8+ cytotoxic and CD4+ helper T-cell responses that target and kill E6/E7-expressing tumor cells; used as a boost to enhance HPV-directed immunity.
YES
INDIRECT
Vaccinia vector vaccine primes HPV16 E7-specific CD8+ T cells; these CTLs recognize E7 peptides on MHC I of tumor cells and kill them via perforin/granzyme-mediated cytolysis (with CD4 help).
Recombinant vaccinia viral vector vaccine expressing HPV16/18 E6/E7 tumor antigens used as a boost to enhance HPV-specific immune responses.
Recombinant vaccinia viral vector that delivers and expresses HPV16/18 E6/E7 tumor antigens in host antigen-presenting cells, leading to MHC I/II presentation and induction of HPV-specific CD8+ cytotoxic and CD4+ helper T-cell responses that target and kill E6/E7-expressing tumor cells; used as a boost to enhance HPV-directed immunity.
YES
INDIRECT
Vaccine delivers HPV18 E6/E7 to APCs, inducing E6-specific CD8+ T cells that recognize E6 peptides on MHC I of tumor cells and kill them via perforin/granzyme cytotoxicity.
Recombinant vaccinia viral vector vaccine expressing HPV16/18 E6/E7 tumor antigens used as a boost to enhance HPV-specific immune responses.
Recombinant vaccinia viral vector that delivers and expresses HPV16/18 E6/E7 tumor antigens in host antigen-presenting cells, leading to MHC I/II presentation and induction of HPV-specific CD8+ cytotoxic and CD4+ helper T-cell responses that target and kill E6/E7-expressing tumor cells; used as a boost to enhance HPV-directed immunity.
YES
INDIRECT
Vaccinia-vectored vaccine drives APC presentation of HPV18 E7 peptides, inducing HPV-specific CD8+ T cells that recognize E7 on MHC I of tumor cells and kill them via perforin/granzyme (and Fas/FasL) pathways.
Human IgG1κ monoclonal antibody targeting CD38 on clonal plasma cells; mediates complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity/phagocytosis, and apoptosis, and modulates immune cells to reduce pathogenic monoclonal immunoglobulin/light-chain production.
Human IgG1κ monoclonal antibody targeting CD38 on clonal plasma cells; induces CDC, ADCC, and ADCP and can trigger apoptosis. Also depletes CD38+ immunosuppressive cells (e.g., Tregs, Bregs, MDSCs), reducing pathogenic monoclonal immunoglobulin/light-chain production.
YES
DIRECT
Anti-CD38 IgG1 binds CD38 and triggers complement-dependent cytotoxicity, Fc-mediated ADCC by NK cells, antibody-dependent phagocytosis, and can induce apoptosis of CD38+ cells.
Type II glycoengineered anti-CD20 monoclonal antibody with enhanced ADCC and direct cell death activity, used to deplete CD20+ B cells.
A type II glycoengineered humanized IgG1 anti-CD20 monoclonal antibody that binds CD20 on B cells and, through enhanced affinity for Fc gamma RIIIa (CD16), mediates strong antibody-dependent cellular cytotoxicity and induces direct, caspase-independent cell death, leading to depletion of CD20-positive B cells (with relatively less complement activation than type I anti-CD20 mAbs).
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its Fc engages CD16a on NK/effector cells to trigger ADCC against CD20+ B cells. CD16a-expressing cells are not killed.